We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $12 · 2 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Emergent BioSolutions (EBS) Secures $64.5M Contract Modification - GuruFocus
Emergent BioSolutions (EBS) Secures $64.5M Contract Modification GuruFocus
Emergent BioSolutions Wins $64.5 Million US Government Contract Modification for BAT
Emergent BioSolutions receives $64.5 million contract modification for BAT® to support U.S. biodefense strategy - marketscreener.com
Emergent BioSolutions receives $64.5 million contract modification for BAT® to support U.S. biodefense strategy marketscreener.com
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy - The Manila Times
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy The Manila Times
Emergent Biosolutions Receives $64.5 Million Contract Modification For Bat® To Support U.S. Biodefense Strategy - TradingView
Emergent Biosolutions Receives $64.5 Million Contract Modification For Bat® To Support U.S. Biodefense Strategy TradingView
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 04. 30. | After market close (AMC) | $0.11 | — | — | $177.5M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $1.19 | — | — | $222.2M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-3.03 | — | — | $848.9M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-5.23 | — | — | $555.1M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 03. 09. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 12. 16. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2026Q1 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 577,128 | $4.79B | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 258,500 | $3.2B | 0.01% | — | New position |
See new positions, full exits, and weight changes.